Innovative therapeutic approaches for the 2019-novel coronavirus [supplements: COVID-19 Variant Network, COVID-19 Variant Supplement, sex as a biological variable supplement]

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 170629, 175564, 175494, 171486

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $779,937
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principle Investigator

    Pending
  • Research Location

    Canada, Americas
  • Lead Research Institution

    CHU de Québec
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    Gender

  • Study Subject

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The 2019-novel coronavirus (SARS CoV-2) is a major sanitary and economical threat to all countries. Development of effective antivirals is a major global priority especially early in the epidemic when vaccines are unavailable. This proposal aims at discovering and evaluating active compounds by rational design through 3D modeling of key viral proteins and also by analyzing cellular gene signatures induced by the virus. In-depth evaluation of selected compounds will include in vitro, ex vivo (human bronchial epithelium tissues) and in vivo (animal models) studies. These approaches, mostly based on drug repurposing (new indication for an existing drug), will result in rapid identification of anti-SARS CoV-2 compounds with accelerated clinical development.